JWCTF OTC

JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical entity currently in the clinical development phase, dedicated to the discovery, manufacturing, and commercialization of advanced cell-based immunotherapeutic solutions. Its core mission is to combat both hematological cancers (blood cancers) and various solid tumors. The company's innovative treatments encompass cell-derived immunotherapies, particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, which leverage a patient's own immune cells to target and eliminate cancerous cells. Leading its clinical efforts is Carteyva (relmacabtagene autoleucel), an anti-CD19 CAR-T therapeutic agent aimed at various forms of blood cancer. Beyond its flagship product, JW (Cayman) Therapeutics maintains a promising product pipeline. This includes JWCAR129, an autologous CAR-T therapy for treating multiple myeloma; JWATM204, a T-cell receptor (TCR) T-cell therapy candidate for hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell therapy that mimics T-cell receptors, specifically designed to target alpha-fetoprotein in HCC. Established in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.